Posted on 22/12/2009 in Pharmaceutical Company Product News Sanofi Pasteur has entered into an agreement with Syntiron which will see the firm gain the license to develop and commercialise its prophylactic vaccine against Staphylococcus infections.
As part of the agreement, Sanofi Pasteur will support the joint, pre-clinical development of the product alongside Syntiron and will assume responsibility for all future developments and approvals relating to the vaccine.
The conditions it prevents include methicillin-resistant Staphylococcus aureus or MRSA, the latter of which is responsible for several difficult-to-treat infections that are resistant to many antibiotics and penicillin.
Wayne Pisano, president and chief executive officer of Sanofi Pasteur, stated: "Along with our development of a vaccine to prevent Clostridium difficile infection, the successful development of a vaccine to prevent MRSA would be a major achievement in combating hospital-associated infections."
In October, Sanofi Pasteur revealed that a trial into its H1N1 vaccines Panenza (15 mcg dose, non-adjuvanted) and Humenza (3.8 mcg dose, adjuvanted) found that both provoke a robust immune response in humans. Other news stories from 22/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
